Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are Actuate Therapeutics Insiders Buying or Selling?
Actuate Therapeutics (ACTU) has had no reported insider transactions in the past 90 days. The most recent was TODD THOMSON, who sold 280,000 shares at $5.80 on January 5, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the ACTU AI Score. For government officials trading this stock, see ACTU congressional trading.
Recent Actuate Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| TODD THOMSON | Jan 5, 2026 | Sell | 280,000 | $5.8 | $1.6M |
| Bios Clinical Opportunity Fund, LP | Jun 27, 2025 | Buy | 71,428 | $0 | $0 |
| BIOS Fund II NT, LP | Jun 27, 2025 | Buy | 71,428 | $0 | $0 |
| BIOS Fund III, LP | Jun 27, 2025 | Buy | 71,428 | $0 | $0 |
Frequently Asked Questions: Actuate Therapeutics Insider Trading
Actuate Therapeutics insiders have not reported any transactions in the past 90 days.
The most recent sale was by TODD THOMSON who sold 280,000 shares on January 5, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
THOMSON TODD S has sold the most ACTU stock in the last 2 years, with a total value of $1.6M.
The total value of insider transactions for Actuate Therapeutics in the last 2 years is negative, amounting to -$1.6M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
